By the Peptide Marketing team, iComChain LLC · Last updated: 16 November 2026
Which peptides can be advertised? For a research-use-only (RUO) store the honest answer is that no compound is pre-approved for ads, and some carry far more risk than others. Google, Meta, Microsoft and payment processors judge each product by its name, how it is presented and what regulators have said about it. This guide is for owners and marketers of RUO peptide stores. It shows how to sort a catalog into three risk tiers, why compounds that match approved drug ingredients sit at the top, what the FDA has said in 2026, and how to structure campaigns so one product does not put the whole account at risk. It is general information, not legal advice, and it contains no dosing, efficacy or human-use information.
- Risk is set per product, but enforcement lands on the account. One high-risk listing can produce strikes that affect every campaign.
- Highest risk: compounds that share a name with an approved drug’s active ingredient, such as semaglutide and tirzepatide, and the GLP-1 compounds FDA has named in its 2026 warnings.
- Elevated risk: compounds FDA has written about in its compounding safety lists or reviewed at its July 2026 advisory committee, plus blends, kits and anything sold beside reconstitution supplies.
- Lower risk is relative. It means fewer triggers, not approval. Google’s unapproved substances policy still applies.
- Names and pages move products between tiers. Outcome claims raise the tier. Disguised names are a separate violation.
- Structure is about clean data, not hiding. Advertise only what you are prepared to defend, and disclose the whole catalog to your processor.
- Why the answer depends on the product
- The three risk tiers at a glance
- Highest risk: approved drug ingredients and GLP-1s
- Elevated and lower risk: what FDA’s compounding lists tell you
- How names and landing pages change the tier
- Structuring the catalog and campaigns
- The catalog risk-sort checklist
- FAQ
- Sources
1. Why the answer depends on the product
Ad platforms do not publish a list of peptides you may advertise. They publish rules about categories of product and presentation, and they apply them product by product.
- Google Ads. The Healthcare and medicines policy does not allow certain products “regardless of any claims of legality”. Its examples include products that are not government approved and are marketed as safe or effective, products subject to government or regulatory action or warning, and products with names confusingly similar to an unapproved product. Google’s list of unapproved pharmaceuticals and supplements says it is not exhaustive, so a compound’s absence from it is not a clearance.
- Google Merchant Center. The Shopping version of the Healthcare and medicines policy uses the same unapproved substances wording for listings, and allows prescription drugs only from certified online pharmacies.
- Prescription drug terms. Google’s restricted drug terms policy restricts prescription drug terms in ads, landing pages and keywords, and requires certification to target them in the US, Canada and New Zealand. Its October 2025 update names online pharmacies, telemedicine providers and manufacturers as the businesses that certify. An RUO supplier is none of those.
- Meta and Microsoft. Both run their own pharmaceutical and drug ad policies. We could not open the current text of either when writing this guide, so we do not summarise them. Read Meta’s Drugs and Pharmaceuticals standard and Microsoft Advertising’s healthcare and pharmacy policy in its help centre before you plan spend on either.
- Payment processors. Stripe’s restricted businesses list prohibits “incorrectly labeled research chemicals” and restricts card-not-present sales of prescription-only products. PayPal’s Acceptable Use Policy prohibits products that present a risk to consumer safety. Underwriters read your catalog to decide where you fall.
All of these reviewers read the same evidence regulators read. Under 21 CFR 201.128, intended use can be shown by labeling claims, advertising matter and the circumstances of distribution. A product page is all three.
Google’s repeat-violation procedure lists Unapproved substances by name: a warning, then account holds, then suspension after a third strike. Strikes are counted against the account, not the product. That is why the catalog sort comes before campaign building.
2. The three risk tiers at a glance
The tiers below are our working framework, not a platform category. They rank products by how many known triggers they carry.
Lower risk is not approval. Every tier is judged with the landing page and the rest of the site.
| Tier | What puts a product here | Google Ads and Shopping | Meta and Microsoft | Payment processors |
|---|---|---|---|---|
| Highest | Name matches an approved drug’s active ingredient; compound named in FDA’s 2026 GLP-1 statements | Restricted drug term plus unapproved substances and regulatory-warning triggers. Do not advertise. | Treat as not advertisable unless the current policy text clearly says otherwise for your business type | Closest to prescription-only restrictions. Highest chance of decline or termination. |
| Elevated | Named on FDA’s category 2 or withdrawn-nomination tables, reviewed at the July 2026 advisory committee, or named in a warning letter; blends and kits | Regulatory-warning trigger. Frequent disapprovals; isolate or exclude. | Check current policy text before any spend | Must be disclosed. Expect enhanced review. |
| Lower | No approved-drug name match, no FDA mention found, accurate research-only page | May be approved, may still be disapproved under unapproved substances | Check current policy text before any spend | Normal high-risk underwriting for the category |
Platform behaviour depends on the reviewer and the page. Tiers are a planning tool; confirm against current policy text.
3. Highest risk: approved drug ingredients and GLP-1s
A compound sits in the top tier when its name is the active ingredient of an FDA-approved prescription drug. Semaglutide and tirzepatide are the clearest examples. Three triggers stack on such a product at once:
- Restricted drug terms. The name is a prescription drug term, so its use in ads, keywords and landing pages is restricted to certified businesses.
- Regulatory warnings. FDA has written directly about these compounds being sold as research products.
- Consumer intent. Search traffic for these names is overwhelmingly about personal use, which is the use an RUO label says you do not sell for.
What FDA said in 2026
FDA’s page on concerns with unapproved GLP-1 drugs, current as of 1 October 2026, is the most direct statement for RUO sellers. It says FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that were “falsely labeled” for research purposes or not for human consumption. The same page says FDA monitors the internet and has issued warning letters to stop illegally marketed semaglutide and tirzepatide.
On compounding, the page says retatrutide and cagrilintide “cannot be used in compounding under federal law”, that they are not components of FDA-approved drugs, and that FDA has warned telehealth companies, ingredient distributors and outsourcing facilities over retatrutide. It also says FDA is not aware of any lawful basis for compounding with semaglutide salt forms.
FDA’s 2026 warning letters to peptide sellers point the same way. The Gram Peptides letter (31 March 2026) and the TXP Innovations letter (24 August 2026) quote product-page text about body weight, glucose and diabetes. Our RUO website compliance checklist summarises six of these letters.
Do not advertise these products on any paid channel, do not bid on their names, and keep them out of every product feed connected to an ad account. Whether to sell them at all is a legal decision for the owner and their counsel, and your processor must know if you do.
4. Elevated and lower risk: what FDA’s compounding lists tell you
Most RUO catalog items are not approved drug ingredients. Many of them have still been written about by FDA, mostly in the context of pharmacy compounding.
The 503A bulk substance categories
FDA’s 503A bulk substances page explains that a pharmacy may compound with a bulk substance that has a USP or NF monograph, is a component of an approved drug, or appears on the 503A bulks list. Nominated substances awaiting review are sorted into categories: category 1 may be eligible; category 2 raises significant safety risks; category 3 lacked sufficient supporting information.
FDA’s page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, lists GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10 in its category 2 table. A second table lists substances that were previously in category 2 and whose nominations were withdrawn. It includes AOD-9604, BPC-157, CJC-1295, GHK-Cu (injectable routes), KPV, Melanotan II, MOTs-C, Semax, Selank, thymosin alpha-1 and the thymosin beta-4 fragment also known as TB-500.
The July 2026 advisory committee
FDA’s Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to discuss BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon for the 503A bulks list. In its 23 July presentation FDA proposed that BPC-157 and its acetate not be included, and its 24 July presentation made the same proposal for emideltide. Those are FDA staff proposals, not final decisions, and we did not find posted votes or minutes. Check the meeting page for the current outcome.
They are about compounding pharmacies, not RUO sales, and they do not say these substances are illegal to sell. For advertising they matter because Google’s policy lists “government or regulatory action or warning” as a trigger. A compound that appears in an FDA safety table belongs in the elevated tier.
Page-level factors that make any product elevated
- Blends and multi-compound kits. The Royal Peptides letter cited a mixed multi-pack kit and a blend.
- Reconstitution supplies sold alongside. Several 2026 letters treated bacteriostatic water sold beside peptides as a drug.
- Calculators and guides that describe preparation for use.
What lower risk means
A product belongs in the lower tier only if its name matches no approved drug ingredient, you found no FDA list or letter naming it, and its page is accurate and claim-free. Re-check this list each quarter, because FDA pages change. Lower-tier products are the only ones we would consider for Search and Shopping, and even they may be disapproved.
5. How names and landing pages change the tier
A compound’s tier starts with what it is. Presentation can raise it, never lower it.
Things that raise the tier
- Outcome or condition words in titles, descriptions or headings: weight, fat, muscle, healing, ageing, sleep or any disease name.
- Comparisons with approved medicines, or brand drug names anywhere on the page.
- Study summaries framed as benefits. The 2026 letters quoted “studied for” and “research shows” phrasing.
- Dosing, administration or preparation content, and images of syringes or self-administration.
- Reviews or testimonials describing personal results.
Presentation examples
| Element | Raises the risk | Accurate and neutral |
|---|---|---|
| Product title | Compound name plus an outcome word or a brand drug comparison | Compound name, amount per vial, purity, “for laboratory research use only” |
| Description | Summaries of what studies suggest it does in the body | Sequence or formula, molecular weight, form, storage, lot and certificate of analysis |
| Images | Syringes, people, before-and-after visuals | Brand graphics, lab-setting images and documentation |
| Related items | Bacteriostatic water, kits and calculators on the same page | Other research materials and documentation |
Things that do not lower it
- Disclaimers. Google applies its policy regardless of any claims of legality, and FDA’s letters looked past research-use labels.
- Coded names. Nicknames, abbreviations, misspellings or numbers in place of a compound name do not change the product. Google’s Circumventing systems policy treats attempts to evade review as a violation in its own right, and the unapproved substances policy covers names confusingly similar to an unapproved product.
- Separate domains or hidden pages. Moving a product does not change what it is, and showing reviewers different content is cloaking.
Our product page template and feed optimization guide show accurate, claim-free titles and pages. For keyword choices by risk, see peptide keyword research.
6. Structuring the catalog and campaigns
The goal is that ads only ever point at products you have decided to advertise, and that every reviewer sees the same site customers see.
In the catalog
- Tag every product with a tier in your store, and record the reason and the date you checked it.
- Keep tier tags in the feed as custom labels so you can filter Shopping and Performance Max campaigns by them.
- Exclude highest-tier products from ad destinations. Merchant Center’s excluded destination attribute keeps a product out of Shopping ads and other destinations. Elevated products should usually be excluded too.
In the ad account
- Build Search and Shopping around lower-tier products and brand terms. Send ads to product or category pages that contain only those items.
- Do not run broad, feed-wide Performance Max. Limit listing groups to lower-tier labels, and add brand-safe negative keywords. Our guide to Performance Max for peptides covers the setup.
- Turn off automatically created dynamic ads that can pick up any page on the domain.
- Never retry a disapproved product with a renamed copy. Fix the page or stop advertising it.
Separating campaigns stops high-risk products from being submitted for review over and over, which limits strikes. It does not shield the account from what is on the website, because Google reviews the destination and the business behind it. If you are already dealing with a suspension, start with our suspension recovery guide and our Merchant Center recovery service.
On Meta and Microsoft
Plan these channels from the current policy text, not from what worked for another store. Start with brand and lower-tier products only, read every rejection reason, and stop a campaign rather than appeal repeatedly with small wording changes. Microsoft Advertising can import Google Ads campaigns, so check that excluded products and negative keywords carry across before any import goes live.
With payment processors and email
- Disclose the whole catalog, including every highest and elevated item, to every processor. A processor that discovers an undisclosed product line can close the account and hold funds. Our chargebacks and processor redundancy guide covers honest disclosure.
- Apply the same tiers to email. Campaigns are advertising matter too; feature lower-tier products and keep claims out.
Our services for Google Ads for peptides, Google Shopping for peptides, peptide email marketing and peptide payment processing all start from this sort.
7. The catalog risk-sort checklist
- Export the full catalog, including variants, kits and supplies.
- Check each name against approved drug ingredients. Any match goes to highest risk.
- Check FDA’s 2026 GLP-1 statement. Any compound it names goes to highest risk.
- Check FDA’s compounding safety tables and advisory committee pages. Any compound named goes to elevated.
- Search fda.gov warning letters for each compound name. Any match goes to elevated or higher.
- Mark blends, kits and anything sold with reconstitution supplies as elevated.
- Read every lower-tier page and remove outcome words, study-benefit framing, dosing and testimonials.
- Add tier custom labels to the feed and set excluded destinations for highest and elevated items.
- Rebuild campaign product filters so only lower-tier labels can serve.
- Remove highest-tier names from keywords and add them as negatives.
- Send your processor the updated catalog and keep the confirmation.
- Record the date and sources checked, and repeat next quarter.
8. FAQ
Which peptides can be advertised on Google?
Google publishes no list of approved peptides. Its unapproved substances policy applies regardless of any claims of legality and its list is not exhaustive. In our experience only accurately presented, lower-risk products are realistic candidates, and they can still be disapproved.
Can I advertise semaglutide or tirzepatide as research products?
We advise against it. Both are active ingredients of approved prescription drugs, so restricted drug term rules apply, and FDA’s 2026 GLP-1 page says it has warned companies selling them falsely labeled for research purposes.
Does a research-use-only disclaimer change the risk tier?
No. Google’s policy applies regardless of claims of legality, and FDA’s 2026 warning letters looked past research-use labels to the product pages. The tier depends on what the product is and how it is presented.
Is BPC-157 banned?
FDA’s compounding pages list BPC-157 among substances previously in category 2 whose nominations were withdrawn, and in July 2026 FDA proposed it not be added to the 503A bulks list. Those pages concern compounding. For advertising, that regulatory attention puts it in the elevated tier.
Will excluding high-risk products protect my ad account?
It reduces repeated disapprovals and strikes, but it does not hide the website. Google reviews destinations and the business, so the whole site needs to be accurate and claim-free.
Can I rename a product so it passes review?
No. Coded or similar names do not change the product, Google’s policy covers confusingly similar names, and evading review is a separate violation under its Circumventing systems policy.
Do I need to tell my payment processor about high-risk products?
Yes. Give every processor the full, accurate catalog. An undisclosed product line can lead to termination and held funds.
Get your catalog sorted before you spend
Peptide Marketing works only with research-use-only peptide brands. We will go through your catalog, feed and landing pages, assign each product a risk tier, and tell you which campaigns we would build first. We do not help disguise products or work around platform policies.
Prefer email? Write to hello@peptidemarketing.info.
Sources
- FDA: Concerns with unapproved GLP-1 drugs, Bulk substances that may present significant safety risks, 503A bulk substances, PCAC July 2026 meeting, and warning letters to Gram Peptides, TXP Innovations and Royal Peptides
- eCFR: 21 CFR 201.128
- Google: Healthcare and medicines, Unapproved pharmaceuticals list, Restricted drug terms, October 2025 update, Repeat violations, Circumventing systems, Merchant Center healthcare policy and Excluded destination
- Meta: Drugs and Pharmaceuticals. Stripe: Restricted businesses. PayPal: Acceptable Use Policy
General information for businesses selling research-use-only products, not legal or regulatory advice. Sources read on 16 November 2026; policies and FDA pages change.
Leave a Reply